ABSTRACT

Background: Hyponatremia, a electrolyte imbalance as serum sodium concentration of less than 135mEq/L. Hyponatremia is most common electrolyte disorder, with prevalence of 20% to 35% among the hospitalized patients. This is more common in the elderly patients due to the multiple comorbidities, multiple medications and lack of access to food. Tolvaptan is a selective, nonpeptide antagonist that blocks the arginine vasopressin from binding to V2 receptors of distal nephron, induces the excretion of electrolyte-free water without changing the total level of electrolyte excretion. Objective: To study the safety and efficacy of tolvaptan in hyponatraemic patients. Methodology: An ambidirectional cohort study design was conducted at Mallige Hospital, located in the heart of Bengaluru, the capital of Karnataka state of India. This study recorded 300 patients according to inclusion and exclusion criteria from ICU, Male ward and female ward and medical record department. Result: This study shows that sodium level of patients before administration of tolvaptan is 121 mEq/L in 21 patients (14.1%), 125 mEq/L in 19 patients (12.9) and 131 mEq/L in 1 patient (0.7%). The sodium level after the administration of tolvaptan is 138 mEq/L in 42 patients (28.4%), 136 mEq/L in 26 patients (17.6%) and 135 mEq/L in 1 patient (0.7%). Conclusion: The study revealed that the hyponatraemic patients who is treated with tolvaptan having higher efficacy than the patients who is treated with the IVF NS as a standard treatment. Keywords: Hyponatremia, chronic kidney disease, SIADH, Tolvaptan, ADPKD
Publication date: 01/04/2026

https://www.ijbpas.com/pdf/2026/April/MS_IJBPAS_2026_10022.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2026/15.4.10022